"Prodrug" strategies applied to new generation pet imaging agent

“前药”策略应用于新一代宠物显像剂

• 批准号: 386605-2010
• 负责人: Phenix, Christopher
• 金额: $ 2.33万
• 依托单位: Lakehead University
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=507146
• 关键词: Prodrug; strategies; applied; new; generation

Positron emission tomography (PET) is a powerful nuclear-based imaging technique that allows the functional, quantitative, kinetic and tomographic (3D) visualization of physiological and biochemical processes. The technique relies on the injection of a radiopharmaceutical probe that is designed to interact with a specific biomolecule identified to play an important role in a disease process (these biomolecules are known as biomarkers). The ability to visualize the presence and function of a specific biomarker can provide scientists and physicians with information vital for the diagnosing, characterization, staging, and treatment of that disease. Given the recent progress made by molecular biologists in identifying new biomarkers coupled with the world shortage of medical isotopes, a high demand now exists for the development of new generation PET imaging agents.

正电子发射断层扫描（PET）是一种功能强大的基于核的成像技术，可以对生理和生化过程进行功能、定量、动力学和断层扫描（3D）可视化。该技术依赖于注射放射性药物探针，该探针被设计为与被鉴定为在疾病过程中起重要作用的特定生物分子相互作用（这些生物分子被称为生物标志物）。 可视化特定生物标志物的存在和功能的能力可以为科学家和医生提供对该疾病的诊断，表征，分期和治疗至关重要的信息。 鉴于分子生物学家在鉴定新的生物标志物方面取得的最新进展，加上世界上医用同位素的短缺，现在对新一代PET成像剂的开发存在很高的需求。